MRK241101C90000
- 14.55
- 0.000.00%
Merck & Co Newsroom
Merck Is Maintained at Buy by Citigroup
Merck & Co Analyst Ratings
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating
This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $147
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $135
Merck & Company (MRK) Receives a Buy From Berenberg Bank
Goldman Sachs Adjusts Price Target on Merck to $139 From $140
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125